Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    C4 Therapeutics Inc.

    NASDAQ: CCCC · Real-Time Price · USD
    1.56
    -0.07 (-4.29%)
    At close: Jun 17, 2025, 10:07 AM

    C4 Therapeutics Statistics

    Share Statistics

    C4 Therapeutics has 71.01M shares outstanding. The number of shares has increased by 3.17% in one year.

    Shares Outstanding

    n/a
    		 71.01M

    Shares Change (YoY)

    n/a
    		 3.17%

    Shares Change (QoQ)

    n/a
    		 0.57%

    Owned by Institutions (%)

    n/a
    		 92.49%

    Shares Floating

    n/a
    		 54.24M

    Failed to Deliver (FTD) Shares

    n/a
    		 172

    FTD / Avg. Volume

    n/a
    		 0.02%

    Short Selling Information

    The latest short interest is 6.17M, so 8.68% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 6.17M

    Short % of Shares Out

    n/a
    		 8.68%

    Short % of Float

    n/a
    		 9.38%

    Short Ratio (days to cover)

    n/a
    		 6.32

    Valuation Ratios

    The PE ratio is -2.37 and the forward PE ratio is null. C4 Therapeutics's PEG ratio is 0.06.

    PE Ratio

    n/a
    		 -2.37

    Forward PE

    n/a
    		 n/a

    PS Ratio

    n/a
    		 7.02

    Forward PS

    n/a
    		 3.2

    PB Ratio

    n/a
    		 1.16

    P/FCF Ratio

    n/a
    		 -3.82

    PEG Ratio

    n/a
    		 0.06
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for C4 Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 5.71, with a Debt / Equity ratio of 0.3.

    Current Ratio

    n/a
    		 5.71

    Quick Ratio

    n/a
    		 5.71

    Debt / Equity

    n/a
    		 0.3

    Debt / EBITDA

    n/a
    		 -0.64

    Debt / FCF

    n/a
    		 -1.01

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 $323,490.91

    Profits Per Employee

    n/a
    		 $-957,418.18

    Employee Count

    n/a
    		 110

    Asset Turnover

    n/a
    		 0.1

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 131K

    Effective Tax Rate

    n/a
    		 -0.12%

    Stock Price Statistics

    The stock price has increased by -60.63% in the last 52 weeks. The beta is 2.95, so C4 Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.95

    52-Week Price Change

    n/a
    		 -60.63%

    50-Day Moving Average

    n/a
    		 1.45

    200-Day Moving Average

    n/a
    		 3.58

    Relative Strength Index (RSI)

    n/a
    		 55.01

    Average Volume (20 Days)

    n/a
    		 1,088,896

    Income Statement

    In the last 12 months, C4 Therapeutics had revenue of 35.58M and earned -105.32M in profits. Earnings per share was -1.52.

    Revenue

    n/a
    		 35.58M

    Gross Profit

    n/a
    		 35.58M

    Operating Income

    n/a
    		 -119.61M

    Net Income

    n/a
    		 -105.32M

    EBITDA

    n/a
    		 -103.37M

    EBIT

    n/a
    		 -105.19M

    Earnings Per Share (EPS)

    n/a
    		 -1.52
    Full Income Statement

    Balance Sheet

    The company has 55.5M in cash and 65.76M in debt, giving a net cash position of -10.26M.

    Cash & Cash Equivalents

    n/a
    		 55.5M

    Total Debt

    n/a
    		 65.76M

    Net Cash

    n/a
    		 -10.26M

    Retained Earnings

    n/a
    		 -633.7M

    Total Assets

    n/a
    		 319.52M

    Working Capital

    n/a
    		 191.72M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -65.16M and capital expenditures -180K, giving a free cash flow of -65.34M.

    Operating Cash Flow

    n/a
    		 -65.16M

    Capital Expenditures

    n/a
    		 -180K

    Free Cash Flow

    n/a
    		 -65.34M

    FCF Per Share

    n/a
    		 -0.94
    Full Cash Flow Statement

    Margins

    Gross margin is 100%, with operating and profit margins of -336.15% and -295.96%.

    Gross Margin

    n/a
    		 100%

    Operating Margin

    n/a
    		 -336.15%

    Pretax Margin

    n/a
    		 -295.6%

    Profit Margin

    n/a
    		 -295.96%

    EBITDA Margin

    n/a
    		 -290.49%

    EBIT Margin

    n/a
    		 -336.15%

    FCF Margin

    n/a
    		 -183.61%

    Dividends & Yields

    CCCC does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CCCC is $12, which is 636.2% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $12

    Price Target Difference

    n/a
    		 636.2%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 3
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Scores

    Altman Z-Score

    n/a
    		 -2.71

    Piotroski F-Score

    n/a
    		 4

    Add to Watchlist